T1	Person 21 24	age
T2	Value 8 17	>18 years
R1	Has_value Arg1:T1 Arg2:T2	
T3	Condition 48 71	acute coronary syndrome
T4	Condition 73 76	ACS
R2	Subsumes Arg1:T3 Arg2:T4	
T5	Condition 88 111	coronary artery disease
T6	Condition 113 116	CAD
T7	Qualifier 81 87	stable
R3	Subsumes Arg1:T5 Arg2:T6	
R4	Has_qualifier Arg1:T5 Arg2:T7	
*	OR T3 T5
T8	Procedure 143 146	PCI
T9	Mood 130 138	eligible
R5	Has_mood Arg1:T8 Arg2:T9	
T10	Post-eligibility 148 211	Patient is willing and able to provide informed written consent
T11	Condition 225 240	able to receive
T12	Procedure 254 280	dual anti-platelet therapy
T13	Temporal 241 250	12 months
R6	Has_temporal Arg1:T12 Arg2:T13	
T14	Procedure 299 302	PCI
T15	Temporal 293 298	index
R7	Has_temporal Arg1:T14 Arg2:T15	
T16	Observation 282 289	Failure
R8	Has_context Arg1:T14 Arg2:T16	
T17	Post-eligibility 304 355	Patient or physician refusal to enroll in the study
T18	Condition 376 392	CYP2C19 genotype
T19	Temporal 393 415	prior to randomization
T20	Reference_point 402 415	randomization
R9	Has_index Arg1:T19 Arg2:T20	
R10	Has_temporal Arg1:T18 Arg2:T19	
T21	Procedure 425 442	revascularization
T22	Mood 417 424	Planned
T23	Qualifier 446 456	any vessel
R12	Has_mood Arg1:T21 Arg2:T22	
T24	Temporal 457 492	within 30 days post-index procedure
T25	Reference_point 477 492	index procedure
R13	Has_index Arg1:T24 Arg2:T25	
T26	Temporal 524 555	within 12 months post-procedure
T27	Reference_point 546 555	procedure
R15	Has_index Arg1:T26 Arg2:T27	
T28	Qualifier 500 523	of the target vessel(s)
R16	Has_temporal Arg1:T28 Arg2:T26	
R14	Has_temporal Arg1:T23 Arg2:T24	
*	OR T23 T28
T29	Scope 446 555	any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure
R11	Has_scope Arg1:T21 Arg2:T29	
T30	Drug 588 599	clopidogrel
T31	Drug 603 613	ticagrelor
*	OR T30 T31
T32	Temporal 614 650	within the 12 month follow up period
T33	Procedure 664 680	elective surgery
T34	Mood 652 663	example for
R17	Has_mood Arg1:T33 Arg2:T34	
T35	Scope 588 612	clopidogrel or ticagrelo
R18	Has_temporal Arg1:T35 Arg2:T32	
*	OR T35 T33
T36	Measurement 682 698	Serum creatinine
T37	Value 699 709	>2.5 mg/dL
R19	Has_value Arg1:T36 Arg2:T37	
T38	Temporal 710 742	within 7 days of index procedure
T39	Reference_point 727 742	index procedure
R20	Has_index Arg1:T38 Arg2:T39	
R21	Has_temporal Arg1:T36 Arg2:T38	
T40	Measurement 744 758	Platelet count
T42	Value 759 788	<80,000 or >700,000 cells/mm3
T41	Measurement 793 815	white blood cell count
T43	Value 816 832	<3,000 cells/mm3
R22	Has_value Arg1:T41 Arg2:T43	
R23	Has_value Arg1:T40 Arg2:T42	
*	OR T40 T41
T44	Temporal 876 914	within 7 days prior to index procedure
T45	Reference_point 899 914	index procedure
R24	Has_index Arg1:T44 Arg2:T45	
T46	Scope 744 832	Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3
R25	Has_temporal Arg1:T46 Arg2:T44	
T47	Condition 928 951	intracranial hemorrhage
T48	Condition 959 975	hypersensitivity
T49	Drug 979 990	clopidogrel
T50	Drug 994 1004	ticagrelor
T51	Drug 1008 1029	any of its components
*	OR T50 T49
T52	Scope 979 1004	clopidogrel or ticagrelor
R26	Subsumes Arg1:T52 Arg2:T51	
R27	Has_scope Arg1:T48 Arg2:T52	
T53	Non-query-able 1031 1149	Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint
T54	Non-query-able 1151 1192	Patient previously enrolled in this study
T55	Condition 1205 1213	pregnant
T56	Condition 1215 1224	lactating
T57	Mood 1229 1247	planning to become
T58	Condition 1248 1256	pregnant
T59	Temporal 1257 1273	within 12 months
R28	Has_temporal Arg1:T58 Arg2:T59	
R29	Has_mood Arg1:T58 Arg2:T57	
*	OR T55 T56 T58
T60	Procedure 1299 1315	organ transplant
T61	Mood 1319 1339	is on a waiting list
T62	Procedure 1347 1363	organ transplant
R30	Has_mood Arg1:T62 Arg2:T61	
*	OR T60 T62
T63	Procedure 1410 1422	chemotherapy
T64	Mood 1373 1385	is receiving
T65	Mood 1389 1409	scheduled to receive
*	OR T64 T65
T66	Scope 1373 1409	is receiving or scheduled to receive
R31	Has_scope Arg1:T63 Arg2:T66	
T67	Temporal 1423 1467	within 30 days before or after the procedure
T68	Reference_point 1454 1467	the procedure
R32	Has_index Arg1:T67 Arg2:T68	
R33	Has_temporal Arg1:T66 Arg2:T67	
T69	Procedure 1490 1515	immunosuppressive therapy
T70	Condition 1529 1546;1561 1568	immunosuppressive disease
T71	Condition 1550 1568	autoimmune disease
*	OR T70 T71 T69
T72	Condition 1576 1604	human immunodeficiency virus
T73	Condition 1606 1633	systemic lupus erythematous
*	OR T72 T73
T74	Scope 1576 1633	human immunodeficiency virus, systemic lupus erythematous
R34	Subsumes Arg1:T71 Arg2:T74	
T75	Procedure 1671 1699	oral anticoagulation therapy
T76	Multiplier 1663 1670	chronic
R35	Has_multiplier Arg1:T75 Arg2:T76	
T77	Drug 1707 1727	vitamin K antagonist
T78	Drug 1729 1754	direct thrombin inhibitor
T79	Drug 1756 1775	Factor Xa inhibitor
*	OR T79 T78 T77
T80	Scope 1707 1775	vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor
R36	Subsumes Arg1:T75 Arg2:T80	
T81	Drug 1797 1808	simvastatin
T82	Drug 1809 1819	lovastatin
*	OR T82 T81
T83	Multiplier 1820 1830	> 40 mg qd
T84	Temporal 1778 1789	Concomitant
R37	Has_temporal Arg1:T81 Arg2:T84	
R38	Has_temporal Arg1:T82 Arg2:T84	
R39	Has_multiplier Arg1:T82 Arg2:T83	
R40	Has_multiplier Arg1:T81 Arg2:T83	
T85	Drug 1851 1875	potent CYP3A4 inhibitors
T86	Drug 1877 1887	atazanavir
T87	Drug 1889 1903	clarithromycin
T88	Drug 1905 1914	indinavir
T89	Drug 1916 1928	itraconazole
T90	Drug 1930 1942	ketoconazole
T91	Drug 1944 1954	nefazodone
T92	Drug 1956 1966	nelfinavir
T93	Drug 1968 1977	ritonavir
T94	Drug 1979 1989	saquinavir
T95	Drug 1991 2004	telithromycin
T96	Drug 2009 2021	voriconazole
T97	Drug 1851 1864;2026 2034	potent CYP3A4 inducers
T98	Drug 2036 2049	carbamazepine
T99	Drug 2051 2064	dexamethasone
T100	Drug 2066 2079	phenobarbital
T101	Drug 2081 2090	phenytoin
T102	Drug 2092 2100	rifampin
T103	Drug 2106 2117	rifapentine
*	OR T86 T87 T88 T89 T90 T91 T92 T93 T94 T95 T96
*	OR T98 T99 T100 T101 T102 T103
T104	Scope 2036 2117	carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine
R41	Subsumes Arg1:T97 Arg2:T104	
T105	Scope 1877 2021	atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole
R42	Subsumes Arg1:T85 Arg2:T105	
T106	Temporal 1832 1843	Concomitant
R43	Has_temporal Arg1:T97 Arg2:T106	
R44	Has_temporal Arg1:T85 Arg2:T106	
T107	Condition 2120 2141	Non-cardiac condition
T108	Observation 2151 2166	life expectancy
T109	Temporal 2170 2188	less than one year
R45	Has_temporal Arg1:T108 Arg2:T109	
R46	Has_context Arg1:T107 Arg2:T108	
T110	Condition 2252 2270	hepatic impairment
T111	Qualifier 2245 2251	severe
R47	Has_qualifier Arg1:T110 Arg2:T111	
T112	Condition 2297 2315	bleeding diathesis
T113	Condition 2319 2331	coagulopathy
*	OR T113 T112 T114
T114	Procedure 2347 2365	blood transfusions
T115	Mood 2335 2346	will refuse
R48	Has_mood Arg1:T114 Arg2:T115	
T116	Condition 2389 2410	pathological bleeding
T117	Qualifier 2382 2388	active
R49	Has_qualifier Arg1:T116 Arg2:T117	
T118	Qualifier 2420 2426	active
T119	Condition 2427 2457	gastrointestinal (GI) bleeding
R50	Has_qualifier Arg1:T119 Arg2:T118	
R51	Subsumes Arg1:T116 Arg2:T119	
T120	Condition 2459 2476	Inability to take
T121	Drug 2477 2484	aspirin
T122	Multiplier 2500 2514	100 mg or less
R52	Has_multiplier Arg1:T121 Arg2:T122	
R53	AND Arg1:T120 Arg2:T121	
T123	Condition 2524 2539	substance abuse
